Rosner Serena, Giladi Nir, Orr-Urtreger Avi
The Genetic Institute, Tel-Aviv Sourasky Medical Center, Tel-Aviv University, Tel-Aviv, Israel.
Acta Pharmacol Sin. 2008 Jan;29(1):21-34. doi: 10.1111/j.1745-7254.2008.00731.x.
Parkinson's disease (PD) is a neurodegenerative disorder affecting a significant proportion of the ageing population. The etiology is unknown and it is likely due to a multifactorial interaction of genes and the environment on the background of ageing. Findings in the last decade suggest that the contribution of genetics to familial forms of PD is much greater than previously appreciated. Twelve loci are now associated with highly penetrant autosomal dominant or recessive PD, and causative mutations have been identified in eight genes with mutation carriers often characterized by a phenotype indistinguishable from idiopathic disease. To date, PD pharmacotherapy is symptomatic only and does not slow disease progression. Understanding how genetic mutations cause familial PD is likely to clarify molecular mechanisms underlying PD in general and will provide a guide for the development of novel therapies, both preventative and palliative, applicable to all forms of parkinsonism. This review outlines the advances in the study of the genetic background of PD and their possible clinical implications.
帕金森病(PD)是一种神经退行性疾病,影响着相当一部分老年人群。其病因尚不清楚,可能是在衰老背景下基因与环境多因素相互作用的结果。过去十年的研究结果表明,遗传学在家族性帕金森病中的作用比之前认为的要大得多。目前已有12个基因座与高度显性的常染色体显性或隐性帕金森病相关,并且在8个基因中发现了致病突变,突变携带者的表型通常与特发性疾病难以区分。迄今为止,帕金森病的药物治疗仅为对症治疗,无法减缓疾病进展。了解基因突变如何导致家族性帕金森病可能会阐明帕金森病的一般分子机制,并为开发适用于所有形式帕金森症的新型预防和姑息治疗方法提供指导。本综述概述了帕金森病遗传背景研究的进展及其可能的临床意义。